Status:
COMPLETED
Medical Need of OAC Reversal
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Brief Summary
This is a retrospective, observational, claims cohort study to assess, for adult patients initiating an oral anticoagulant for NVAF
Detailed Description
This is a retrospective, observational, claims cohort study to assess, for adult patients initiating an oral anticoagulant for NVAF, the incidence rates of emergency surgery, major bleeding due to tra...
Eligibility Criteria
Inclusion
- \>18 year old non-valvular atrial fibrillation (NVAF) patients
- Prescribed dabigatran, rivaroxaban, apixaban, edoxaban or warfarin
- Patients with confirmed date of initiation of OACs
- Patients with a minimum of 6 months of enrolment data prior to index date
- Has an index date between 14th of March 2011 to 30 June, 2016
Exclusion
- Patients receiving two or more oral anti-coagulants at the same time at index date
- Patients with prescriptions of index treatment in the 6 months prior to index date
- Patients without enrolment period of at least six month in the database
Key Trial Info
Start Date :
October 15 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 10 2017
Estimated Enrollment :
53969 Patients enrolled
Trial Details
Trial ID
NCT03254147
Start Date
October 15 2017
End Date
November 10 2017
Last Update
March 4 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nippon Boehringer Ingelheim Co., Ltd.
Tokyo, Japan